EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application

Jason C Wong iD, Aselle Barak

Pharmacy · 23.01.2024 · 12 (1) · 19

DOI: 10.3390/pharmacy12010019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacy, online erschienen am 23.01.2024. Verfasst von Jason C Wong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, CA 91766, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED) is a common condition that affects mainly older individuals and women. It is characterized by reduced tear production and increased tear evaporation. Symptoms include burning, irritation, tearing, and blurry vision. This paper reviews key trials of various new DED treatments, including their mechanism of action, study outcomes, safety, and efficacy. The paper also includes a critical assessment of the trial’s validity and potential pharmacy applications of these new treatments. The literature search was conducted through PubMed, the Cochrane Central Register of Controlled Trials, and Google Scholar. The keywords “Dry Eye Disease”, “lifitegrast”, “cyclosporine”, “loteprednol etabonate”, “varenicline nasal spray”, and “perfluorohexyloctane” were used to identify these medications’ landmark trials. The articles deemed these medications safe and efficacious, with minimal side effects. Our randomized controlled trial validity comparison found the trials robust with predominantly low bias. Cyclosporine and loteprednol are effective when artificial tears fail, while perfluorohexyloctane reduces tear film evaporation and is preservative-free. Varenicline offers drug delivery via the nasal route and is appropriate for contact lens users. In conclusion, these FDA-approved novel medications exhibit safety and efficacy in managing DED. Further research is needed on long-term outcomes, efficacy, and side-effect comparisons, and combination therapy benefits.

Schlagwörter

Stichwörter der Autor:innen

cyclosporinedry eye diseaselifitegrastloteprednol etabonateperfluorohexyloctanevarenicline nasal spray

Autor:innen und Institutionen

  • Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, CA 91766, USA.
  • College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.

ORCID-Profile: Jason C Wong

Zitieren

APA

Wong, J. C., & Barak, A. (2024). Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application. Pharmacy, 12(1), 19. https://doi.org/10.3390/pharmacy12010019

Vancouver

Wong JC, Barak A. Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application. Pharmacy. 2024;12(1):19. doi:10.3390/pharmacy12010019

BibTeX
@article{Wong2024,
  author = {Wong, Jason C and Barak, Aselle},
  title = {Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application},
  journal = {Pharmacy},
  year = {2024},
  volume = {12},
  number = {1},
  pages = {19},
  doi = {10.3390/pharmacy12010019}
}
Kostenlos starten →